Category: GI Dynamics
GI Dynamics says a head-to-head comparison of its Endobarrier weight loss device with standard gastric bypass surgery in Type II diabetics shows similar improvements to glucose metabolism.
Here's a look at some of the top Wall Street stories for medical device companies this week: Report: ViewRay tables $52m IPO; GI Dynamics exercises 1-for-10 reverse split; BSD Medical rebrands as Perseon, wins expanded FDA nod for MicroThermX; Positron conducts 1-for-400 reverse stock split
GI Dynamics has conducted a 1-for-10 reverse stock split in an effort to boost its lagging stock price.
GI Dynamics (ASX:GID) said it conducted a 1-for-10 reverse stock split in an effort to boost its flagging share price.
Here's a look at some of the top Wall Street stories for medical device companies this week: Diabetes: Valeritas sets terms for $75m IPO; New Siemens healthcare unit to start in May; Australia halts trading in GI Dynamics shares; Bayer aims to boost drugs sales, margins over next 3 years
Here's a look at some of the top regulatory stories for medical device companies this week: Olympus sold 'superbug' scopes without our clearance; FDA clears 1 Hospira plant, flags another; GI Dynamics plunges 50% after FDA halts trial; Sunshine Heart stops trial enrollment after patient deaths; Petition accuses Bayer's Conceptus of altering Essure trial data
Shares of GI Dynamics lose 50% of their value after the company reveals that the FDA halted enrollment a clinical trial of its EndoBarrier weight loss device.
GI Dynamics asks the Australian Stock Exchange to halt trading in shares of its stock pending an announcement from the weight loss device maker.
The Australian stock exchange today granted a request from GI Dynamics (ASX:GID) to halt trading in shares of its stock, pending a company announcement between now and March 9.